Children 6 to 23 months of age who receive trivalent inactivated flu vaccine concurrently with the 13-valent pneumococcal conjugate vaccine are at increased risk of febrile seizures, according to researchers at the CDC and Harvard Medical School.
Children 6 to 23 months of age who receive trivalent inactivated flu vaccine (TIV) concurrently with the 13-valent pneumococcal conjugate vaccine (PCV13) are at increased risk of febrile seizures, according to researchers at the Centers for Disease Control and Prevention (CDC) in Atlanta and Harvard Medical School in Boston.
Frank DeStefano, MD, MPH, director of the CDC’s Immunization and Safety Office, and Grace M. Lee, MD, MPH, assistant professor of Population Medicine at Harvard Medical School, presented their findings at a recent meeting of the CDC’s Advisory Committee on Immunization Practices (ACIP) in Atlanta. DeStefano noted that fever after vaccination is common and might increase the risk of febrile seizures. He estimated that when given concurrently, TIV and PCV13 might account for approximately 60 seizures per 100,000 children and that such seizures typically occur the day after vaccination.
Preliminary results from the Vaccine Safety Datalink suggest that unless administered concurrently with PCV13, the 2010/2011 TIV used in the United States is not associated with an increased risk of febrile seizures in children 6 to 23 months of age.
DeStefano put these findings into perspective. “Febrile seizures associated with vaccine administration are associated with a good prognosis, although they can scare parents and caregivers,” he said.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.